We detect the medicine you take from your breath and more

nGageIT Digital Medicine

Smarter Medicine

Technology

Applications

Integration

Data & Analytics

Medication Adherence

nGageIT Digital Medicine

We detect the medicine you take from your breath and more

Technology

Applications

Integration

Data & Analytics

Breath Sensor Technology

nGageIT Digital Medicine

We detect the medicine you take from your breath and more

Technology

Applications

Integration

Data & Analytics

nGageIT Digital Medicine

We detect the medicine you take from your breath and more

Technology

Applications

Integration

Data & Analytics

Improving Outcomes

nGageIT Digital Medicine

We detect the medicine you take from your breath and more

Technology

Applications

Integration

Data & Analytics

Innovating Healthcare

We detect the medication you take with your breath and more

nGageIT Digital Medicine is a breath diagnostics company pioneering new medical treatment breakthroughs. This starts with medication adherence, treatment verification and compliance, and progresses to patient wellness factors and biomarkers, and more advanced diagnostic applications.

Breath diagnostics and adherence-monitoring technology provides real-time insights into patient treatment behaviors

We help providers and physicians treat their patients better by filling in the gaps in adherence, wellness, and behavioral data, enabling the development of effective and efficient interventions, improved adherence, and improved patient health and outcomes.
Learn how we can address specific market challenges
We deliver significant Ai-driven insights into patient behaviors and treatment results.
Learn more about how our Data & Analytics can drive patient outcomes

Medication non-adherence is an up-to USD $500 billion dollar problem in the United States annually

Chronic Conditions 50%
About one half of adults or 117 million have one chronic condition and almost one-third have two or more.
Medication Adherence 53%
Among chronic disease patients, approximately 50% do not take their medications as prescribed (one quarter are never even filled).
Treatment Compliance 32%
Nearly one-third of heart attack patients are not persistent with their prescribed medications by 6 months.

More than 80% of lung cancer patients will survive for at least a year if diagnosed at the earliest stage compared to around 15% for people diagnosed with the most advanced stage of disease.

Survival rates comparing stage 1 and stage 4 lung cancer

0%
Stage 1 The overall 5-year survival rate for stage 1A lung cancer is 49 percent and for 1B is 45 percent
0%
Stage 4 Less than 10% survival rate for diagosed Stage 4 cancers

The global clinical trials market is said to be expected to reach USD 65.2 billion by 2025.

The globalization of clinical trials (led by the emergence of CROs as a driving force in the clinical trials market), development of new treatments and evolving technologies such as personalized medicine and programs as well as digital monitoring services along with the increasing demand for data and analytics by way of CRO support all are said to play key roles in shaping the future of clinical trials.
However, the complexity of trials, patient recruitment, adoption of technology, regulatory requirements, high cost levels and many others issues 
create challenges conducting and working in the clinical trials market. High rates of failure resulting from lengthy and complex study designs and the constraints driven by the complexities of guidelines have resulted in all-time high clinical trials.  Additionally, patient access to appropriate clinical trials and engagement is declining, and staff and operations management is more challenging than ever.
The overall cost of failed clinical trails is extremely high, with estimates varying between $800 million and $1.4 billion USD.
0%
Percentage of Clinical Trials that Fail Due To Non-Adherence
0%
The standard estimates for overall probability of clinical succes http://blogs.sciencemag.org/pipeline/archives/2018/02/02/a-new-look-at-clinical-success-rates

We help patients, providers, physicians, practitioners, and health systems provide better treatment programs, more efficient treatment plans and diagnostics solutions, more timely interventions and urgent patient care, and more improved patient outcomes.

nGageIT patent pending Nanosmart™ technology is being used to develop portable accurate mobile handheld breath diagnostic technology that can be easily deployed in health systems at an affordable cost.

We are also developing the worlds largest data library of cancer bio-markers in the breath, with the ability to detect numerous forms of cancers and other illnesses. The metabolism of people with lung cancer, pancreatic cancer and breast cancer is different to that of healthy people and this is reflected in the chemical signature of their breath.

Medication Adherence

Real-time patient medication adherence monitors and tracks treatment progress and provides information back to patients and providers.

Wellness Tracking

Patient-informed wellness data is collected during the treatment program, helping to inform a deeper understanding of the patient experience.

Patient Biomarkers

Our Nanoparticle Biosensor™ tracks patient biomarkers passively, relaying health information back into the cloud and informing physicians of health states.

Real-Time Interventions

Understanding treatment difficulties earlier means more efficient and effective interventions can be provided to patients.

Patient Incentives

Participation in the program enables patients to receive incentives in addition to improved wellness, such as insurance or program-based incentives.

Data & Analytics

All data is sent and stored in the cloud, enabling advanced Ai-driven modeling that will understand and inform patient treatment programs.

Program Optimization

Treatment, healthcare, and insurance programs benefit substantially from higher adherence, better patient outcomes, and lower costs.

Payor Modeling

Macro patient stratification informs more nuanced cost models, enabling insurance health-driven incentives for patient populations.

News & Updates:

Our Partners

PlugandPlay
MetroHealth